Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Net Income towards Common Stockholders (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Net Income towards Common Stockholders data on record, last reported at -$319.2 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 115.91% to -$319.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$975.3 million, a 89.53% decrease, with the full-year FY2025 number at -$804.0 million, down 74.94% from a year prior.
  • Net Income towards Common Stockholders reached -$319.2 million in Q1 2026 per PCVX's latest filing, down from -$247.8 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for PCVX hit a ceiling of $92.7 million in Q3 2023 and a floor of -$623.7 million in Q4 2023.
  • A 5-year average of -$145.1 million and a median of -$111.9 million in 2024 define the central range for Net Income towards Common Stockholders.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 259.99% in 2023 and fell as far as 699.14% in 2023.
  • Tracing PCVX's Net Income towards Common Stockholders over 5 years: stood at -$78.0 million in 2022, then crashed by 699.14% to -$623.7 million in 2023, then surged by 79.85% to -$125.7 million in 2024, then tumbled by 97.14% to -$247.8 million in 2025, then decreased by 28.81% to -$319.2 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for PCVX at -$319.2 million in Q1 2026, -$247.8 million in Q4 2025, and -$213.1 million in Q3 2025.